KR102421013B1 - 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 - Google Patents

삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 Download PDF

Info

Publication number
KR102421013B1
KR102421013B1 KR1020170060713A KR20170060713A KR102421013B1 KR 102421013 B1 KR102421013 B1 KR 102421013B1 KR 1020170060713 A KR1020170060713 A KR 1020170060713A KR 20170060713 A KR20170060713 A KR 20170060713A KR 102421013 B1 KR102421013 B1 KR 102421013B1
Authority
KR
South Korea
Prior art keywords
trigeminal
formula
painful
trigeminal neuralgia
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020170060713A
Other languages
English (en)
Korean (ko)
Other versions
KR20170131241A (ko
Inventor
조민재
황선관
이한주
Original Assignee
에스케이바이오팜 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스케이바이오팜 주식회사 filed Critical 에스케이바이오팜 주식회사
Publication of KR20170131241A publication Critical patent/KR20170131241A/ko
Application granted granted Critical
Publication of KR102421013B1 publication Critical patent/KR102421013B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020170060713A 2016-05-19 2017-05-16 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 Active KR102421013B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160061386 2016-05-19
KR20160061386 2016-05-19

Publications (2)

Publication Number Publication Date
KR20170131241A KR20170131241A (ko) 2017-11-29
KR102421013B1 true KR102421013B1 (ko) 2022-07-14

Family

ID=60325324

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020170060713A Active KR102421013B1 (ko) 2016-05-19 2017-05-16 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Country Status (14)

Country Link
US (2) US11207295B2 (enExample)
EP (1) EP3459542B1 (enExample)
JP (1) JP6960415B2 (enExample)
KR (1) KR102421013B1 (enExample)
CN (1) CN109310669B (enExample)
AU (1) AU2017267160B2 (enExample)
CA (1) CA3024284C (enExample)
DK (1) DK3459542T3 (enExample)
ES (1) ES2887338T3 (enExample)
MX (1) MX389613B (enExample)
PL (1) PL3459542T3 (enExample)
PT (1) PT3459542T (enExample)
RU (1) RU2751504C2 (enExample)
WO (1) WO2017200317A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3035674T3 (en) 2016-12-14 2025-09-08 Sk Biopharmaceuticals Co Ltd Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease
IL281559B2 (en) * 2018-09-21 2025-06-01 Sk Biopharmaceuticals Co Ltd (r)-1-phenyl-2-tetrazolyl ethyl carbamate derivatives and formulations comprising same for use in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
KR20210062029A (ko) 2018-10-19 2021-05-28 에스케이바이오팜 주식회사 카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100323410A1 (en) 2009-06-22 2010-12-23 Sang Chul Lim Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
US20110111467A1 (en) 2009-10-15 2011-05-12 Sang Chul Lim Method for Preparation of Carbamic Acid (R)-1-Aryl-2-Tetrazolyl-Ethyl Ester
KR101286499B1 (ko) * 2005-04-22 2013-07-16 에스케이바이오팜 주식회사 신경치료용 아졸 화합물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) * 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
DE2628420A1 (de) * 1976-06-24 1978-01-05 Bayer Ag 1-acyloxy-2-imidazolyl-1-phenyl- aethane, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide und nematizide
EP0959882A4 (en) * 1996-12-31 2001-12-05 N-BONDED UREAUTIES AND CARBAMATES OF HETEROCYCLIC THIOESTERS
MXPA03007721A (es) * 2001-02-27 2004-11-12 Johnson & Johnson Compuesto de carbamato para su uso en el tratamiento del dolor.
JP4227121B2 (ja) * 2005-06-08 2009-02-18 独立行政法人科学技術振興機構 神経因性疼痛治療剤
KR20140009244A (ko) * 2010-11-11 2014-01-22 애크런 몰레큘스 게엠베하 통증 치료용 화합물 및 방법
SI3054950T1 (sl) * 2014-05-09 2017-12-29 Tecnimede-Sociedade Tecnico-Medicinal, S.A. (r)-pirindol in njegove farmacevtsko sprejemljive soli za uporabo v medicini

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101286499B1 (ko) * 2005-04-22 2013-07-16 에스케이바이오팜 주식회사 신경치료용 아졸 화합물
US20100323410A1 (en) 2009-06-22 2010-12-23 Sang Chul Lim Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
US20110111467A1 (en) 2009-10-15 2011-05-12 Sang Chul Lim Method for Preparation of Carbamic Acid (R)-1-Aryl-2-Tetrazolyl-Ethyl Ester

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Epilepsy Research, 92(2-3):89-124 (2010.12.01.)
European Journal of Medicinal Chemistry, 36(5):421-433 (2001)
NEUROLOGIC ASPECTS OF SYSTEMIC DISEASE PART I: "Chapter 33: Fibromyalgia", HANDBOOK OF CLINICAL NEUROLOGY, 119:513-527 (2014)
Novel Neurotherapeutic for Epilepsy, Neuropathic Pain and Bipolar Disorder, YKP3089 - SK biopharmaceuticals, <https://www.epilepsy.com/sites/core/files/atoms/files/6-6_S_James_Lee.pdf>(2012.12.31.)

Also Published As

Publication number Publication date
BR112018073556A2 (pt) 2019-03-19
MX2018014081A (es) 2019-09-02
AU2017267160A1 (en) 2018-12-13
CN109310669A (zh) 2019-02-05
EP3459542A4 (en) 2020-01-08
US12611395B2 (en) 2026-04-28
KR20170131241A (ko) 2017-11-29
CN109310669B (zh) 2022-02-22
ES2887338T3 (es) 2021-12-22
RU2018144784A (ru) 2020-06-19
CA3024284A1 (en) 2017-11-23
EP3459542B1 (en) 2021-06-30
US20190175555A1 (en) 2019-06-13
RU2018144784A3 (enExample) 2020-08-11
JP2019516722A (ja) 2019-06-20
US11207295B2 (en) 2021-12-28
US20220087976A1 (en) 2022-03-24
DK3459542T3 (da) 2021-09-13
EP3459542A1 (en) 2019-03-27
PL3459542T3 (pl) 2021-12-27
MX389613B (es) 2025-03-20
CA3024284C (en) 2024-01-23
RU2751504C2 (ru) 2021-07-14
AU2017267160B2 (en) 2022-11-10
PT3459542T (pt) 2021-08-24
WO2017200317A1 (ko) 2017-11-23
JP6960415B2 (ja) 2021-11-05

Similar Documents

Publication Publication Date Title
JP6257326B2 (ja) 神経因性疼痛におけるマロノニトリルアミドの使用
US12611395B2 (en) Use of carbamate compound for preventing or treating trigeminal neuralgia
JP7071287B2 (ja) 繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用
CN105142637A (zh) 用于预防或治疗干眼症的含瑞巴派特或其前药的口服药物组合物
KR102421006B1 (ko) 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도
JP4746714B2 (ja) 線維筋痛症治療用医薬組成物
KR102635938B1 (ko) 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
KR102921943B1 (ko) 중첩발작의 예방, 경감 또는 치료에 대한 카바메이트 화합물의 용도
KR102635941B1 (ko) 진전 또는 진전 증후군의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
JP2021503010A (ja) 欠神発作又は欠神発作を示すてんかんの予防、軽減又は治療のためのカルバメート化合物の使用
KR20210047888A (ko) 카바메이트 화합물 및 이를 포함하는 배합물의 급성 스트레스 장애 또는 외상 후 스트레스 장애의 예방, 경감 또는 치료를 위한 용도
HK40003859A (en) Use of carbamate compound for preventing or treating trigeminal neuralgia
HK40003859B (en) Use of carbamate compound for preventing or treating trigeminal neuralgia
KR20210062029A (ko) 카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도
JO et al. Use of carbamate compound for preventing or treating trigeminal neuralgia
BR112018073556B1 (pt) Uso de um composto de carbamato
HK40015213A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
HK40005640B (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia
HK40005640A (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia
WO2010047295A1 (ja) 帯状疱疹関連痛の予防又は治療薬

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5